Most Recent
Swiss pharmaceutical company Actelion has brought a fourth patent infringement case over plans to launch a generic version of its blood pressure drug in Australia -- against Lupin unit Generic Health -- after firing off cases against three other drug makers.
Cipla Australia wants an undertaking it intends to give pharma company Actelion over plans to launch a generic version of a blood pressure drug to be shielded from rivals Arrotex, Nova Pharmaceuticals and MSN Laboratories, as those companies battle patent infringement claims.
US-based medical device maker OrthAlign has lost its lawsuit alleging Sydney-based surgical technology company Navbit infringed its patent for a technology used to guide the positioning of artificial hip joints during surgery.
A judge hearing a lawsuit against Target and Kmart over alleged knockoffs of Van Cleef & Arpels jewellery has warned the parties against wasting the court's time.
Industry standards group Meat & Livestock Australia can bring a cross-claim for indemnity against the Agricultural Business Research Institute while defending a case alleging it infringed a patent for inferring bovine gene traits.
A recent judgment that clarified the date for assessing best method knowledge for divisional patents appears to create new difficulties for patent applicants, lawyers say.
Bayer and Teva have lost their challenge to Indian drug maker Cipla’s extension of its patent for an allergy medication, with IP Australia finding a failure to pay renewal fees on time was due to a genuine error.
Danish company Vestesen Hybrid Energy has taken Zenith Energy to court for allegedly infringing its patented system for operating an electrical grid where energy is generated by a fluctuating renewable energy source.
Zoetis has been ordered to pay Scidera’s costs of defending an unsuccessful summary dismissal application on a lump sum basis in a dispute over a bovine gene patent, with a judge rejecting its “premature” bid for a set-off.
Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea.